Entitled the 2018 Journal Citation Reports, the report also ranked the journal 23rd out of 133 journals in medical research and experimentation, and 55th out of 222 journals in oncology. The rankings earned the journal a place in Q1 in both categories.
CMB is an English-language journal published by Tianjin Medical University Cancer Institute and Hospital under the auspices of the China Association for Science and Technology and Chinese Anti-Cancer Association.
Caption: The cover of a 2015 issue of the journal CMB [Image courtesy of www.cancerbiomed.org]
According to the report data, papers published in CBM have had growing influence in recent years, having been cited by such internationally renowned journals as Nature, CA-A Cancer Journal for Clinicians, The Lancet, Cancer Cell, and Clinical Cancer Research. The percentage of citations by foreign authors now exceeds 60 percent, indicating that the journal has received the attention of oncologists around the globe.
The predecessor of CBM, the English version of the Chinese Journal of Clinical Oncology, was created in February 2004, in honor of the 100th birth anniversary of Professor Jin Xianzhai, the founding father of oncology in China, and the founder of China’s first journal on oncology, the Chinese version of the Chinese Journal of Clinical Oncology. Launched by Professor Hao Xishan who also served as its editor-in-chief, the English version aims to promote academic exchange in the field of oncology at home and abroad, and promotes the international dissemination of clinical research results and information about diagnosis and treatment in China.
Then, in 2012, with the goal of becoming a world-leading oncology journal, the journal adopted the new name Cancer Biology & Medicine and established an international editorial committee comprising 116 outstanding scholars from 29 countries and regions. As it implements a strict peer review system and conforms to international norms, the journal has joined international publishing groups such as the Committee on Publication Ethics and CrossRef.
The journal is dedicated to reporting on the latest achievements of oncology research at home and abroad, and presenting the progress of research, diagnosis and treatment on indigenous cancer types in China, with comments, reviews, discussions, correspondence and other columns. Special themed issues, including tumor immunotherapy, tumor nanotechnology, genome sequencing and precision tumor treatment, have been published as well, with a focus on papers with a high academic level and high clinical application value to promote the transformation of oncology basics and clinical research.
CBM was included in PubMed Central with full-text open access in 2013 and included in the Science Citation Index in 2017. The journal has been repeatedly honored among the Highest International Impact Academic Journals in China and among Excellent Science and Technology Journals of China's Universities. It was also included in the Key Science and Technology Magazines of China by the Institute of Scientific and Technical Information of China.
Tag: STM journals
Copyright (c) 2007 CAST . All rights reserved. China Association for Science and Technology reserved